The FDA has announced that shortages of Ozempic and Wegovy, which have affected patients for over two years, are now resolved due to improved supplies from manufacturer Novo Nordisk. Although the company can meet the current demand, some patients might still experience supply issues as the drugs move through distribution channels. Additionally, the FDA has also confirmed that other medications like Zepbound and Mounjaro have overcome their shortages. These medications, part of the GLP-1 class, are recognized for their effectiveness in weight management and diabetes treatment, but previous shortages complicated access for many patients.
The resolution of shortages for Ozempic and Wegovy has allowed Novo Nordisk to meet current and future demand in the U.S., as confirmed by the FDA.
Despite resolving long-standing shortages, patients may still encounter supply disruptions as medications transition from manufacturers to distributors and pharmacies.
Collection
[
|
...
]